2019
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precision Oncology 2019, 3: 1-9. PMID: 32923853, PMCID: PMC7446367, DOI: 10.1200/po.19.00087.Peer-Reviewed Original ResearchMetastatic breast cancerEligible patientsBreast cancerExact testHER2-negative breast cancerOngoing phase II trialGenomic profilingPhase II trialProportion of patientsComprehensive genomic profilingRoutine clinical practiceFisher's exact testGenomic tumor profilingArchived tissue samplesII trialMedian timeTRIAL REGISTRATIONTrial participationClinical trialsSpecific genomic changesClinical impactGenomic testing resultsRare subsetPatientsClinical practice
2016
Clinical trial enrollment expansion to the community.
Kostka J, Zerillo J, Kruse A, Sinclair N, Patrick M, McGovern L, Fuller F, O'Neil K, Hixon N, Weeks K, Johnson B, Krop I, Savoie J, Daftary F, Constantine M, Kaddis M, Rossi H, Tahir N, Norden A. Clinical trial enrollment expansion to the community. Journal Of Clinical Oncology 2016, 34: 112-112. DOI: 10.1200/jco.2016.34.7_suppl.112.Peer-Reviewed Original ResearchBreast cancer patientsClinical trial enrollmentClinical trialsEligible patientsTrial enrollmentCancer patientsNew breast cancer patientsNurse telephone callsProportion of patientsClinical trial programPre-screening patientsAcademic medical centerOncology patientsCancer practiceClinician visitsInitial consultationAcademic hospitalMedical CenterTrial discussionsPatientsTrial programClinical teamMultidisciplinary teamNumeric improvementsClinical staff
2013
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
Lin NU, Seah DS, Gelman R, Desantis S, Mayer EL, Isakoff S, DiPiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research And Treatment 2013, 139: 403-410. PMID: 23645007, DOI: 10.1007/s10549-013-2551-9.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerGrade 3/4 non-hematologic toxicitiesHER2-positive metastatic breast cancerNon-hematologic toxicitiesTreatment-related toxicityBreast cancerCommon treatment-related toxicitiesFirst-line patientsProtocol-based therapySecond-line cohortSecond-line patientsSecond-line settingPhase II studyProportion of patientsCombination of vinorelbineCo-primary endpointsEligible patientsFebrile neutropeniaMedian PFSII studyMedian durationObjective responsePrior linesUnacceptable toxicityMedian age